EMERGENT BIOSOLUTIONS INC. OCI, before Reclassifications, Net of Tax, Attributable to Parent
EMERGENT BIOSOLUTIONS INC. (EBS) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of -$1.80 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2024-11-07
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2024-09-30 was -$1.80M, a 185.71% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2024-03-31 was $200.00K.
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2023-09-30 was $2.10M, a 61.54% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2023 was $3.60M, a 82.44% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2022 was $20.50M, a 412.50% increase from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2021 was $4.00M.
- EMERGENT BIOSOLUTIONS INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2020 was -$19.30M.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$1.80M 10-Q · filed 2024-11-07 | -$1.80M derived: sum of 2 quarters · filed 2024-11-07 | -$1.60M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-11-07 | $200.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2024-03-31 | $200.00K 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $3.60M 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $2.10M 10-Q · filed 2024-11-07 | $5.90M derived: sum of 2 quarters · filed 2024-11-07 | $1.40M derived: sum of 3 quarters · filed 2024-11-07 | $12.90M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.80M 10-Q · filed 2024-11-07 | -$700.00K derived: sum of 2 quarters · filed 2024-11-07 | $10.80M derived: sum of 3 quarters · filed 2024-11-07 | $12.10M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | -$4.50M 10-Q · filed 2024-11-07 | $7.00M derived: sum of 2 quarters · filed 2024-11-07 | $8.30M derived: sum of 3 quarters · filed 2024-11-07 | $10.60M derived: sum of 4 quarters · filed 2024-11-07 |
| 2022-12-31 | $11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $12.80M derived: sum of 2 quarters · filed 2024-03-08 | $15.10M derived: sum of 3 quarters · filed 2024-03-08 | $20.50M 10-K · filed 2024-03-08 |
| 2022-09-30 | $1.30M 10-Q · filed 2023-12-11 | $3.60M derived: sum of 2 quarters · filed 2023-12-11 | $9.00M 10-Q · filed 2022-11-09 | $15.10M derived: sum of 4 quarters · filed 2023-12-11 |
| 2022-06-30 | $2.30M 10-Q · filed 2023-12-11 | $7.70M 10-Q · filed 2022-08-02 | $13.80M derived: sum of 3 quarters · filed 2023-12-11 | $11.80M derived: sum of 4 quarters · filed 2023-12-11 |
| 2022-03-31 | $5.40M 10-Q · filed 2023-12-11 | $11.50M derived: sum of 2 quarters · filed 2023-12-11 | $9.50M derived: sum of 3 quarters · filed 2023-12-11 | $9.90M derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-12-31 | $6.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $4.10M derived: sum of 2 quarters · filed 2023-12-11 | $4.50M derived: sum of 3 quarters · filed 2023-12-11 | $4.00M 10-K/A · filed 2023-12-11 |
| 2021-09-30 | -$2.00M 10-Q · filed 2022-11-09 | -$1.60M derived: sum of 2 quarters · filed 2022-11-09 | -$2.10M 10-Q · filed 2022-11-09 | -$12.40M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $400.00K 10-Q · filed 2022-08-02 | -$100.00K 10-Q · filed 2022-08-02 | -$10.40M derived: sum of 3 quarters · filed 2022-08-02 | -$8.20M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$500.00K 10-Q · filed 2022-04-29 | -$10.80M derived: sum of 2 quarters · filed 2022-04-29 | -$8.60M derived: sum of 3 quarters · filed 2022-04-29 | -$8.50M derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | -$10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$8.10M derived: sum of 2 quarters · filed 2022-02-25 | -$8.00M derived: sum of 3 quarters · filed 2022-02-25 | -$19.30M 10-K · filed 2022-02-25 |
| 2020-09-30 | $2.20M 10-Q · filed 2021-11-05 | $2.30M derived: sum of 2 quarters · filed 2021-11-05 | -$9.00M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $100.00K 10-Q · filed 2021-07-30 | -$11.20M 10-Q · filed 2021-07-30 | ||
| 2020-03-31 | -$11.30M 10-Q · filed 2021-04-30 | |||
| 2019-12-31 | -$5.00M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |